Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10111
Title: Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
Authors: Cher, Lawrence M;Murone, Carmel;Lawrentschuk, Nathan L ;Ramdave, Shanker;Papenfuss, Anthony;Hannah, Anthony;O'Keefe, Graeme J;Sachinidis, John I;Berlangieri, Salvatore U;Fabinyi, Gavin;Scott, Andrew M
Affiliation: Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia.
Issue Date: 1-Mar-2006
Citation: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine; 47(3): 410-8
Abstract: PET offers a noninvasive means to assess neoplasms, in view of its sensitivity and accuracy in staging tumors and potentially in monitoring treatment response. The aim of this study was to evaluate newly diagnosed primary brain tumors for the presence of hypoxia, as indicated by the uptake of 18F-fluoromisonidazole (18F-FMISO) and to examine the relationship of hypoxia to the uptake of 18F-FDG and molecular markers of hypoxia.Seventeen patients with suspected primary glioma were enrolled prospectively in this study. Sixteen patients had histology, with 2 having metastatic disease. All patients had PET studies with 18F-FMISO and 18F-FDG and MRI studies. Immunohistochemistry was undertaken with tumor markers of angiogenesis and hypoxia. Patients were monitored for disease progression and statistical analysis of data was performed.Of the 14 patients with histology, 8 died with a median time of 16 mo (range, 2-30 mo) until death. Of those who died, 7 had positive and 1 had negative 18F-FMISO uptake. 18F-FMISO uptake was observed in all high-grade gliomas but not in low-grade gliomas. A significant relationship was found between 18F-FDG or 18F-FMISO uptake and expression of VEGF-R1 and Ki67 expression. Other immunohistochemical markers demonstrated a trend toward increased uptake but none was significant.18F-FMISO PET provides a noninvasive assessment of hypoxia in glioma and was prognostic for treatment outcomes in the majority of patients. 18F-FMISO PET may have a role not only in directing patients toward targeted hypoxic therapies but also in monitoring response to such therapies.
Internal ID Number: 16513609
URI: http://ahro.austin.org.au/austinjspui/handle/1/10111
URL: http://www.ncbi.nlm.nih.gov/pubmed/16513609
Type: Journal Article
Subjects: Adult
Aged
Brain.blood supply.metabolism.radionuclide imaging
Brain Neoplasms.complications.metabolism.radionuclide imaging
Cell Hypoxia
Female
Fluorodeoxyglucose F18.diagnostic use.pharmacokinetics
Glioma.metabolism.radionuclide imaging
Glucose.metabolism
Humans
Male
Metabolic Clearance Rate
Middle Aged
Misonidazole.analogs & derivatives.diagnostic use.pharmacokinetics
Neovascularization, Pathologic.complications.metabolism.radionuclide imaging
Oxygen.metabolism
Radiopharmaceuticals.diagnostic use
Statistics as Topic
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.